Clinical Research Directory
Browse clinical research sites, groups, and studies.
Treatment of ARDS With Sivelestat Sodium
Sponsor: Sichuan Provincial People's Hospital
Summary
Neutrophil elastase (NE) released by neutrophils play an important role in inflammatory cascade and lung tissue injury of ARDS.Inhibition of NE is expected to prevent the pathophysiological process of ARDS and alleviate lung injury. Siverestat sodium is a specific inhibitor of NE, which has been proved by basic and observational clinical studies to be effective in alleviating lung injury of ARDS, but there is a lack of prospective multi-center randomized controlled clinical trials.Therefore, this study was intended to evaluate the efficacy of sivelestat sodium in the treatment of ARDS patients with SIRS in a multicenter randomized controlled clinical trial
Official title: Efficacy of Sivelestat Sodium in the Treatment of ARDS With SIRS, a Multicenter Double-blind Randomized Controlled Clinical Trial
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
324
Start Date
2022-04-18
Completion Date
2026-03-30
Last Updated
2025-05-01
Healthy Volunteers
No
Conditions
Interventions
Sivelestat sodium
4.8mg/kg sivelestat sodium was given in 50ml normal saline, and was continuously pumped in the dark for 24h, equivalent to 0.2mg/kg/h.Applied for 5 consecutive days
Saline
50ml normal saline was continuously pumped in the dark for 24h. Applied for 5 consecutive days
Locations (1)
Sichuan provincial people's hospital
Chengdu, Sichuan Privince, China